Garassino Highlights What’s In Store for Lung Cancer
June 21st 2021Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer
June 18th 2021Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.
Precision Medicine Presents a Disconnect in Oncology Practice
June 16th 2021Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target, present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets within the tumor or within the germline.